Antios Says Its Novel Hepatitis B Mechanism Can Help Toward Functional Cure

First-in-class active-site polymerase inhibitor yields Phase Ib/IIa data showing suppression of HBV DNA. It also demonstrated a good safety profile with normalization of liver enzymes.